A detailed history of Man Group PLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Man Group PLC holds 55,722 shares of VERV stock, worth $253,535. This represents 0.0% of its overall portfolio holdings.

Number of Shares
55,722
Previous 125,591 55.63%
Holding current value
$253,535
Previous $612,000 56.05%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.4 - $7.86 $307,423 - $549,170
-69,869 Reduced 55.63%
55,722 $269,000
Q2 2024

Aug 14, 2024

BUY
$4.76 - $12.79 $525,770 - $1.41 Million
110,456 Added 729.81%
125,591 $612,000
Q1 2024

May 15, 2024

BUY
$10.81 - $17.96 $40,180 - $66,757
3,717 Added 32.55%
15,135 $200,000
Q4 2023

Feb 14, 2024

BUY
$8.84 - $18.7 $100,935 - $213,516
11,418 New
11,418 $159,000

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $273M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.